EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

Megan Palmer iD, Yuanxi Zou iD, Anneke C Hesseling, Louvina van der Laan iD, Ingrid Courtney, Aarti A Kinikar iD, Naresh Sonkawade iD, Mandar Paradkar iD, Vandana Kulkarni iD, Dessa Jean O Casalme, Melchor V G Frias, Heather Draper und 5 weitere

British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1853-1864

DOI: 10.1002/bcp.70005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 17.02.2025. Verfasst von Megan Palmer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa. Hauptthemen laut MEDLINE: Moxifloxacin, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Fluoroquinolones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Unitaid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Moxifloxacin is a priority drug for treating rifampicin‐resistant tuberculosis (RR‐TB). We assessed the pharmacokinetics of a child‐friendly, dispersible 100 mg tablet moxifloxacin formulation (dispersed in water) compared to the standard 400 mg non‐dispersible formulation (crushed and suspended in water) in children and evaluated current dosing recommendations.

Methods

The CATALYST trial investigated the pharmacokinetics of moxifloxacin in children with RR‐TB. Children were enrolled in South Africa, India and the Philippines. Intensive pharmacokinetic sampling was undertaken while children were taking the standard non‐dispersible 400 mg moxifloxacin tablet formulation and repeated after switching to the novel dispersible formulation. Pharmacokinetic data were analysed using population pharmacokinetic modelling. Simulations were performed to evaluate moxifloxacin exposures in children compared to consensus adult reference exposures using current World Health Organization (WHO)‐recommended doses and more recent model‐based doses.

Results

Thirty‐six children were enrolled [median age 4.8 (range 0.4–15) years and weight 15.6 (range 6.9–42.1) kg]. A two‐compartment disposition model with first‐order elimination and delayed absorption was developed. The bioavailability of dispersible versus standard formulations fulfilled standard bioequivalence criterion (ratio 1.05 with 90% confidence interval 0.95–1.15). Simulations showed WHO‐recommended doses achieved exposures similar to those in adults in children >10 kg, while children

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MoxifloxacinTuberculosis, Multidrug-ResistantAntitubercular AgentsFluoroquinolonesHumansChildRifampinChild, PreschoolAdolescentMaleFemaleInfantModels, BiologicalBiological AvailabilityTablets

Stichwörter der Autor:innen

child‐friendly formulationmoxifloxacinpaediatric dosingpaediatric tuberculosispopulation pharmacokinetics

Substanzen

MoxifloxacinRifampinAntitubercular AgentsTabletsFluoroquinolones

Autor:innen und Institutionen

  • Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • B.J. Government Medical College, Pune, India.
  • BJ Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Center for Infectious Diseases in India, Johns Hopkins India, Pune, India.
  • De La Salle Health Sciences Institute, Dasmarinas, The Philippines.

ORCID-Profile: Megan Palmer, Yuanxi Zou, Louvina van der Laan, Aarti A Kinikar, Naresh Sonkawade, Mandar Paradkar, Vandana Kulkarni, Lubbe Wiesner, Mats O Karlsson, Paolo Denti, Elin M Svensson, Anthony J Garcia-Prats

Förderung

  • Unitaid

Zitieren

APA

Palmer, M., Zou, Y., Hesseling, A. C., van der Laan, L., Courtney, I., Kinikar, A. A., Sonkawade, N., Paradkar, M., Kulkarni, V., Casalme, D. J. O., Frias, M. V. G., Draper, H., Wiesner, L., Karlsson, M. O., Denti, P., Svensson, E. M., & Garcia-Prats, A. J. (2025). Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis. British Journal of Clinical Pharmacology, 91(6), 1853-1864. https://doi.org/10.1002/bcp.70005

Vancouver

Palmer M, Zou Y, Hesseling AC, van der Laan L, Courtney I, Kinikar AA, et al. Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis. British Journal of Clinical Pharmacology. 2025;91(6):1853-1864. doi:10.1002/bcp.70005

BibTeX
@article{Palmer2025,
  author = {Palmer, Megan and Zou, Yuanxi and Hesseling, Anneke C and van der Laan, Louvina and Courtney, Ingrid and Kinikar, Aarti A and Sonkawade, Naresh and Paradkar, Mandar and Kulkarni, Vandana and Casalme, Dessa Jean O and Frias, Melchor V G and Draper, Heather and Wiesner, Lubbe and Karlsson, Mats O and Denti, Paolo and Svensson, Elin M and Garcia-Prats, Anthony J},
  title = {Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {6},
  pages = {1853--1864},
  doi = {10.1002/bcp.70005}
}
Kostenlos starten →